Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02372-18. doi: 10.1128/AAC.02372-18. [Epub ahead of print]

PMID:
30670426
2.

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against S. aureus and S. pneumoniae.

Lepak AJ, Zhao M, Liu Q, Wang P, Wang Y, Bader JC, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Dec 17. pii: AAC.02404-18. doi: 10.1128/AAC.02404-18. [Epub ahead of print]

PMID:
30559140
3.

In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.

Kinn PM, Chen DJ, Gihring TM, Schulz LT, Fox BC, McCreary EK, Lepak AJ.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):258-260. doi: 10.1016/j.diagmicrobio.2018.09.017. Epub 2018 Oct 4.

PMID:
30344065
4.

Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01572-18. doi: 10.1128/AAC.01572-18. Print 2018 Nov.

PMID:
30181375
5.

In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01067-18. doi: 10.1128/AAC.01067-18. Print 2018 Sep.

PMID:
29987156
6.

The Wrong Frame of Mind.

McBride JA, Lepak AJ, Dhaliwal G, Saint S, Safdar N.

N Engl J Med. 2018 May 3;378(18):1716-1721. doi: 10.1056/NEJMcps1710814. No abstract available.

PMID:
29719187
7.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

8.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

9.

In vivo infection models in the pre-clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

Andes DR, Lepak AJ.

Curr Opin Pharmacol. 2017 Oct;36:94-99. doi: 10.1016/j.coph.2017.09.004. Epub 2017 Sep 29. Review.

PMID:
28964956
10.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

11.

Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection.

Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00791-17. doi: 10.1128/AAC.00791-17. Print 2017 Aug.

12.

In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00250-17. doi: 10.1128/AAC.00250-17. Print 2017 Jul.

13.

Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.

Lepak AJ, Zhao M, Andes DR.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00281-17. doi: 10.1128/AAC.00281-17. Print 2017 Jul.

14.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00476-17. doi: 10.1128/AAC.00476-17. Print 2017 Jun.

15.

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model.

Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02368-16. doi: 10.1128/AAC.02368-16. Print 2017 May.

16.

Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents.

Zhao M, Lepak AJ, Andes DR.

Bioorg Med Chem. 2016 Dec 15;24(24):6390-6400. doi: 10.1016/j.bmc.2016.11.008. Epub 2016 Nov 9. Review.

PMID:
27887963
17.

Impact of Low Procalcitonin Results on Antibiotic Administration in Hospitalized Patients at a Tertiary Care Center.

Brennan MB, Osterby K, Schulz L, Lepak AJ.

Infect Dis Ther. 2016 Jun;5(2):185-91. doi: 10.1007/s40121-016-0114-1. Epub 2016 Jun 1.

18.
19.

In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.

Lepak AJ, Seiler P, Surivet JP, Ritz D, Kohl C, Andes DR.

Antimicrob Agents Chemother. 2016 May 23;60(6):3626-32. doi: 10.1128/AAC.00363-16. Print 2016 Jun.

20.

In Vivo Pharmacodynamic Evaluation of an FtsZ Inhibitor, TXA-709, and Its Active Metabolite, TXA-707, in a Murine Neutropenic Thigh Infection Model.

Lepak AJ, Parhi A, Madison M, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2015 Oct;59(10):6568-74. doi: 10.1128/AAC.01464-15. Epub 2015 Aug 10.

21.

Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.

Lepak AJ, Marchillo K, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. doi: 10.1128/AAC.04445-14. Epub 2014 Dec 15.

22.

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.

Lepak AJ, Marchillo K, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2015 Feb;59(2):1258-64. doi: 10.1128/AAC.04444-14. Epub 2014 Dec 15.

23.

Antifungal pharmacokinetics and pharmacodynamics.

Lepak AJ, Andes DR.

Cold Spring Harb Perspect Med. 2014 Nov 10;5(5):a019653. doi: 10.1101/cshperspect.a019653. Review.

24.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Lepak AJ, Reda A, Marchillo K, Van Hecker J, Craig WA, Andes D.

Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4. doi: 10.1128/AAC.03572-14. Epub 2014 Aug 4.

25.

Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.

Lewis JS 2nd, Lepak AJ, Thompson GR 3rd, Craig WA, Andes DR, Sabol-Dzintars KE, Jorgensen JH.

Antimicrob Agents Chemother. 2014;58(3):1327-31. doi: 10.1128/AAC.01877-13. Epub 2013 Dec 9.

26.

Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6284-9. doi: 10.1128/AAC.01355-13. Epub 2013 Oct 7.

27.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

28.

Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.

Lepak AJ, Marchillo K, VanHecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.

29.

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.

30.

Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.

Lepak AJ, Marchillo K, Vanhecker J, Andes DR.

Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.

31.

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.

Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.

32.

Antifungal PK/PD considerations in fungal pulmonary infections.

Lepak AJ, Andes DR.

Semin Respir Crit Care Med. 2011 Dec;32(6):783-94. doi: 10.1055/s-0031-1295726. Epub 2011 Dec 13. Review.

PMID:
22167406
33.

Time course global gene expression analysis of an in vivo Candida biofilm.

Nett JE, Lepak AJ, Marchillo K, Andes DR.

J Infect Dis. 2009 Jul 15;200(2):307-13. doi: 10.1086/599838.

Supplemental Content

Loading ...
Support Center